Purchase Testosterone Gel (AndroGel, Cernos) online
How and where to order testosterone gel, injections, capsules and tablets online:
Shop: MEDS DIRECT SHOP
- 30% bonus pills for all reorders
Sellers: TESTOSTERONE STORES
from $5.63 per pack
Testosterone gel 1% 5 g
14, 30, 60, 90 packs
Testosterone brand, Cernos Gel brand, AndroGel generic
Visa, Mastercard, AmEx, Cryptocurrencies
Registered airmail, international delivery service
Worldwide, including USA, UK, Europe, Canada, Australia
Indications and usage:
Testosterone AndroGel and Cernos Gel 1% are indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired).
Hypogonadotropic hypogonadism (congenital or acquired).
As an anabolic steroid for purposes of bodybuilding, to increase athletic ability, to growth of muscle mass, strength, endurance.
Limitations of use:
Safety and efficacy of this medication in men with "age-related hypogonadism" have not been established.
Safety and efficacy of AndroGel 1% in males less than 18 years old have not been established.
Topical testosterone products may have different doses, strengths or application instructions that may result in different systemic exposure.
Dosage and administration:
Prior to initiating Testosterone Gel 1%, confirm the diagnosis of hypogonadism by ensuring that serum testosterone has been measured in the morning on at least two separate days and that these concentrations are below the normal range.
Starting dose of Cernos Gel 1% is 50 mg of testosterone (two 25 mg packets or one 50 mg packet), applied once daily in the morning.
Apply to clean, dry, intact skin of shoulders and upper arms and/or abdomen. Do not apply AndroGel 1% to any other parts of the body including the genitals, chest, armpits (axillae), knees, or back.
Dose adjustment: This medicine can be dose adjusted using 50 mg, 75 mg, or 100 mg of testosterone on the basis of total serum testosterone concentration. The dose should be titrated based on the serum testosterone concentration. Additionally, serum testosterone concentration should be assessed periodically.
Patients should wash hands immediately with soap and water after applying testosterone gel and cover the application site(s) with clothing after the gel has dried. Wash the application site thoroughly with soap and water prior to any situation where skin-to-skin contact of the application site with another person is anticipated.
Dosage forms and strengths:
AndroGel (Testosterone Gel) 1% for topical use is available as follows:
Packets containing 25 mg of testosterone.
Packets containing 50 mg of testosterone.
Cernos Gel (Testosterone) 1% for topical use is available in 5 g packs containing 50 mg of testosterone.
There is one report of acute overdosage with use of an approved injectable testosterone product: this subject had serum testosterone concentrations of up to 11,400 ng/dL with a cerebrovascular accident.
Treatment of overdosage would consist of discontinuation of AndroGel 1%, washing the application site with soap and water, and appropriate symptomatic and supportive care.
Men with carcinoma of the breast or known or suspected prostate cancer.
Women who are pregnant. testosterone may cause fetal harm.
Warnings and precautions:
Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH.
Avoid unintentional exposure of women or children to Cernos Gel 1%. Secondary exposure to testosterone can produce signs of virilization. AndroGel 1% should be discontinued until the cause of virilization is
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products. Evaluate patients with signs or symptoms consistent
with DVT or PE.
Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with use of testosterone replacement therapy.
Exogenous administration of androgens may lead to azoospermia.
Edema, with or without congestive heart failure (CHF), may be a complication in patients with preexisting cardiac, renal, or hepatic disease.
Sleep apnea may occur in those with risk factors.
Monitor serum testosterone, prostate specific antigen (PSA), hemoglobin, hematocrit, liver function tests, and lipid concentrations periodically.
Testosterone gel is flammable until dry.
Adverse reactions, side effects:
Most common adverse reactions (incidence >= 5%) are acne, application site reaction, abnormal lab tests, and prostatic disorders.
To report suspected adverse reactions of AndroGel (Testosterone), contact AbbVie Inc. pharmaceutical company or the U.S. FDA.
To report suspected adverse reactions of Cernos Gel, contact Sun Pharmaceutical Industries or your local FDA.
Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients.
Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of INR and prothrombin time is recommended.
Use of testosterone with adrenocorticotrophic hormone (ACTH) or corticosteroids may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease.
Use in specific populations:
There are insufficient long-term safety data in geriatric patients using AndroGel 1% to assess the potential risks of cardiovascular disease and prostate cancer.
Drug abuse and dependence:
Testosterone Gel 1% is a controlled substance in some countries (for example, Schedule III in the United States and Canada).
Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice.
Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors:
Taking greater dosages than prescribed.
Continued drug use despite medical and social problems due to drug use.
Spending significant time to obtain the drug when supplies of the drug are interrupted.
Giving a higher priority to drug use than other obligations.
Having difficulty in discontinuing the drug despite desires and attempts to do so.
Experiencing withdrawal symptoms upon abrupt discontinuation of use.
"We provided some exciting changes to the study plan within a couple of weeks of treatment dates and the team stepped up, as usual, and put a plan into place to give us the highest chance of success utilizing the criteria we requested."
Our expert preclinical Surgeons and Interventionalists can assist with human factors assessments and evaluating prototypes for your GLP or nonGLP preclinical studies.